Furthermore, 30% of breast cancer patients without heredity were found to have methylation of the BRCA1 and BRCA2 promoter or dysfunctional upstream pathways, leading to descending levels of BRCA1 and BRCA2 (10, 11). This evidence concerns the gene BRCA1 and breast carcinoma.